The BridgeTech Program is a national professional development program that trains researchers and entrepreneurs on how to effectively navigate the commercialisation pathway of new medical technologies.
Convened and administered by Queensland University of Technology, The BridgeTech Program involves a consortium of partners including medtech companies, universities and industry associations. Leveraging off the industry expertise and global networks that the consortium offers, The BridgeTech Program will equip participants with the necessary skills and networks needed to take new medtech to market.
The BridgeTech Program will enable Australia to more effectively capitalise on its world-class medical research sector by providing entrepreneurs and scientists training on the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that contribute to medtech commercialisation. The program is unique in its industry-led medical technology expertise and integration into venture capital and global medical technology networks and its ability to share specific, detailed and practical commercialisation insights.
Launched in April 2018 the program selects up to 100 participants annually from across Australia to take part in face-to-face and online training, presented through an interactive, mobile and self-paced platform that is designed to complement work schedules. Involving online learning and materials, webinars, a touring speaker series and culminating in the 3-day BridgeTech Symposium, the program has a 1 year duration that is accessible from anywhere around Australia.
Selected as part of the MTPConnect Project Fund Program, The BridgeTech Program was awarded industry matched funding in 2018 to deliver this unique education program. In recognising the success and positive impact on the Australian medtech industry, the program was again awarded funding through the Biomedical Translation Bridge (BTB) scheme – more information available on the BTB here.
- 331 early careers researchers have now trained in medical device commercialisation.
- As of June 2020 this has resulted in eight new companies, four products launched and twelve pre-clinical or clinical trial. Networks have developed between participants and industry.
- This project is now funded by the BTB fund.
Listen to the MTPConnect Podcast to hear from QUT Executive Director Professor Lyn Griffiths talk about the program.
Visit the BridgeTech program's website for more information.
LinkedIn: BridgeTech Program
|Consortium lead||Queensland University of Technology|
Agilent Technologies, AusBiotech, Australia China Technology Incubator, Cochlear, Deakin University, Flinders University, Gadens, Hydrix, IDE Group, Life Sciences Queensland, Macquarie University, Magnetica, The Actuator, MTAA, Siemens Healthcare, Stryker, University of Melbourne, University of New South Wales, University of Newcastle & University of Western Australia
|Project duration||February 2018 - September 2019 (Completed)|
|Contact||Kate Nelson, The BridgeTech Program, Queensland University of Technology - firstname.lastname@example.org|